Pharmaceuticals - Community Register

  

Community list of not active orphan medicinal products


WITHDRAWN  

Product information

Lintuzumab

EU orphan designation number: EU/3/09/627
Active ingredient: Lintuzumab
Indication: Treatment of acute myeloid leukaemia
Sponsor: Seattle Genetics UK Limited
c/o Jordans Limited, 20-22 Bedford Row, London WC1R 4JS , United Kingdom

   Public summary of scientific opinion    

 

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
05/05/2009 Centralised Orphan - Designation EMEA/OD/118/08 (2009)3526 of 30/04/2009
17/08/2011 Centralised Orphan - Removal of orphan designation from Community Register